raloxifene hydrochloride has been researched along with Parkinsonian Disorders in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, X; Menniti, FS; Ramirez, AD | 1 |
| Callier, S; Di Paolo, T; Grandbois, M; Morissette, M; Pélaprat, D | 1 |
2 other study(ies) available for raloxifene hydrochloride and Parkinsonian Disorders
| Article | Year |
|---|---|
Repeated estradiol treatment prevents MPTP-induced dopamine depletion in male mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Estradiol; Male; Mice; Mice, Inbred C57BL; Neostriatum; Neuroprotective Agents; Parkinsonian Disorders; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2003 |
Neuroprotective properties of 17beta-estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice.
Topics: Animals; Carrier Proteins; Dopamine; Dopamine Plasma Membrane Transport Proteins; Estradiol; Gene Expression; Male; Membrane Glycoproteins; Membrane Transport Proteins; Mice; Mice, Inbred C57BL; Neostriatum; Nerve Tissue Proteins; Neural Pathways; Neurons; Neuroprotective Agents; Parkinsonian Disorders; Progesterone; Radioligand Assay; Raloxifene Hydrochloride; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; RNA, Messenger; Selective Estrogen Receptor Modulators; Substantia Nigra | 2001 |